LPTX - Flagship Biosciences and Leap Therapeutics ink RNAscope partnership

Leap Therapeutics (LPTX) and Flagship Biosciences announce a partnership to use a clinically validated tumor expression assay utilizing RNAscope and tissue image analysis.In a recent poster shared at the American Association for Cancer Research ((AACR)) Annual Meeting 2021, the companies presented data on the validation of a Dickkopf-1 ((DKK1)) RNAscope chromogenic in situ hybridization ((CISH)) assay and digital image analysis solution.DKK1 is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with a poor prognosis for patients.Flagship conducts the RNAscope assay, image analysis, data analysis, and in-house pathologist review, providing the information needed to make clinical trial enrollment decisions.

For further details see:

Flagship Biosciences and Leap Therapeutics ink RNAscope partnership